Clinical Perspectives


Gynecologic Cancer Genetics and Molecular Medicine Tumor Board at Moffitt Cancer Center

August 30, 2022

GYN Tumor Board Review 640

About 5% to 10% of all gynecologic cancers are hereditary. While it’s not based solely on familial genetic issues, genetic testing can give clues to what types of risk factors some individuals may have. Beyond this, many tumors create their own genetic changes, called somatic, that can mutate genes and may be targeted for new therapies or clinical trial opportunities.

At Moffitt Cancer Center, we offer a highly collaborative Gynecologic Cancer Genetics and Molecular Medicine Tumor Board to ensure that each patient is provided with a highly-targeted treatment plan. This novel, multidisciplinary team is comprised of gynecologic oncologists, medical oncologists, genetic counselors, and other healthcare providers.

Revolutionizing Treatment Through Genetic Testing

The gynecologic oncologists and genetic counselors in our tumor board perform germline and somatic tumor genetic testing to identify the hereditary risk of cancers, as well as to understand what vulnerabilities cancer might have. Through genetic testing, our multidisciplinary team can identify the best course of treatment for current patients, as well as develop preventative strategies for patients with cancer predispositions or gynecologic pre-malignancies.

portrait of blockquote author

"The goal of the Gynecologic Cancer Genetics and Molecular Medicine Tumor Board is to provide a targeted treatment plan at the onset for the best possible outcomes and an enhanced quality of life. There is no redo in cancer treatment."

- Dr. Robert Wenham, Chair, Department of Gynecologic Oncology

Our experts review results from the patient’s tumor genetics and/or inherited gene testing, both of which can have important treatment-related consequences. Inherited gene testing can inform the patient about not only her risk of new cancers but also those of her family. This ensures a whole-patient view to determine the best evidence-based treatment approach. Meeting monthly, the board takes many aspects of care into account and ensures all the latest treatment and clinical trial options are considered before recommending the best course of therapy.

After undergoing genetic testing, each patient receives a personalized medicine and evidence-based treatment plan. Patients who test positive for an inherited gene mutation, which raises their risk of developing gynecologic cancer, can get comprehensive care at Moffitt, including cancer screening tests, preventive strategies, full-health exams, education, and counseling, all provided under one roof. 

portrait of blockquote author

"Our gynecologic oncologists and genetic counselors perform germline and somatic tumor genetic testing to identify the hereditary risk of cancers."

- Jing-Yi Chern, MD, ScM, Chair, Tumor Board

The Gynecologic Cancer Genetics and Molecular Medicine Tumor Board treats invasive cancers and provides recommendations for gynecological cancers, and some benign conditions, as well as preventative screening, surveillance, or treatments for genetic risk syndromes. This unique and specialized board is in addition to our general histological tumor board. This service is provided only for patients at Moffitt Cancer Center and is seamlessly integrated into the care given to our patients. 

To refer a patient to Moffitt, complete our online form or contact a physician liaison for assistance or support.  As part of our efforts to shorten referral times as much as possible, online referrals are typically responded to within 24 - 48 hours.